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Abstract
Background: Perfluorododecanoic acid (PFDoA) is a perfluorinated carboxylic chemical (PFC) that has broad applications
and distribution in the environment. While many studies have focused on hepatotoxicity, immunotoxicity, and reproductive
toxicity of PFCAs, few have investigated renal toxicity.
Methodology/Principal Findings: Here, we used comparative proteomic and metabonomic technologies to provide a
global perspective on renal response to PFDoA. Male rats were exposed to 0, 0.05, 0.2, and 0.5 mg/kg/day of PFDoA for 110
days. After 2-D DIGE and MALDI TOF/TOF analysis, 79 differentially expressed proteins between the control and the PFDoA
treated rats (0.2 and 0.5 mg-dosed groups) were successfully identified. These proteins were mainly involved in amino acid
metabolism, the tricarboxylic acid cycle, gluconeogenesis, glycolysis, electron transport, and stress response. Nuclear
magnetic resonance-based metabonomic analysis showed an increase in pyruvate, lactate, acetate, choline, and a variety of
amino acids in the highest dose group. Furthermore, the profiles of free amino acids in the PFDoA treated groups were
investigated quantitatively by high-coverage quantitative iTRAQ-LC MS/MS, which showed levels of sarcosine, asparagine,
histidine, 1-methylhistidine, Ile, Leu, Val, Trp, Tyr, Phe, Cys, and Met increased markedly in the 0.5 mg dosed group, while
homocitrulline, a-aminoadipic acid, b-alanine, and cystathionine decreased.
Conclusion/Significance: These observations provide evidence that disorders in glucose and amino acid metabolism may
contribute to PFDoA nephrotoxicity. Additionally, a2u globulin may play an important role in protecting the kidneys from
PFDoA toxicity.
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Introduction
Perfluorinated carboxylic chemicals (PFCs) have been manu-
factured and used in various industrial and commercial products
over the past 50 years, including surfactants, lubricants, fire
fighting foams, and cosmetics [1]. Their high-energy carbon-
fluorine bonds enable them to resist hydrolysis, photolysis,
biodegradation, and metabolism, which increases their impact
on environmental and human health [2]. Recent biomonitoring
studies have revealed significant global distribution of PFCs in the
environment, wildlife, human beings [1,3–6], and even remote
areas such as the Arctic [7,8]. Perfluorooctanoic acid (PFOA, C8),
perfluorooctansulfonate (PFOS, C8), and perfluorododecanoic
acid (PFDoA, C12) are the most commonly detected PFCs [9] and
have thus received much attention from toxicologists and
environmental scientists.
The liver and kidney are the main organs for PFCs
bioaccumulation in animals [10]. In addition, the liver is the
primary target organ for PFCs toxicity [11,12], and the kidney is
the main elimination organ for PFCs [13]. Studies have shown
that exposure to PFCs increases the liver-to-body weight ratio,
hepatocellular hypertrophy, and peroxisome proliferation
[11,12,14] and induces adenoma in hepatocytes in laboratory
animals [15,16]; however, few studies have focused on the toxic
effects of PFCs on the kidney. While Kawashima et al. [17]
reported that PFOA induces peroxisomal b-oxidation in rat
kidney, Son et al. [18] observed no renal toxicity in mice orally
exposed to PFOA for 21 days. Our previous study found that
several kidney damage biomarkers (specifically, blood urea
nitrogen (BUN), creatinine, and BUN to creatinine ratio) increased
significantly in rat serum after chronic exposure to PFDoA for 110
days compared with the control group [19], which compelled our
further investigation of the potential renal toxicity of PFCs.
Two-dimensional difference gel electrophoresis (2-D DIGE) is
an efficient and accurate method for the separation of proteins in
complex mixtures and quantifies differential expression in treated
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based screening tool for the analysis of environmental stress
responses in organisms [21]. Metabonomics is a systems biology
approach for determining the endogenous metabolic responses of
living systems using either
1H nuclear magnetic resonance (NMR)
spectroscopy or mass spectrometry in conjunction with statistical
pattern recognition [22].
We used 2-D DIGE followed by mass spectrometric analyses of
individual protein spots to better understand the potential renal
toxicity of PFDoA. NMR-based metabonomic analysis was
employed for lipid and aqueous kidney extracts to determine the
varied metabolite profiles from normal and PFDoA treated rats. In
addition, to accurately detect variations in the profiles of free
amino acids in kidneys exposed to PFDoA, we used iTRAQH–
LC–MS/MS with 42 internal standards of physiological amino
acids and amines for absolute quantification by isotope ratio
analysis. These data will help estimate an organism’s internal
reserves and the degree of metabolic disintegration under the
influence of xenobiotics and adaptive abilities of the target organs
and the organism as a whole. This research will not only explore
the underlying mechanisms of PFDoA nephrotoxicity but will also
provide a reference for assessing the risk of PFCs to human health.
Materials and Methods
Ethics Statement
This study was conducted in accordance with the Animal Ethics
Committee of Institute of Zoology, Chinese Academy of Sciences.
The institute does not issue a number or ID to any animal study,
but the ethical committee guides the animal use.
Experiment animals and design
Male Sprague-Dawley rats (230–240 g) were obtained from the
Weitong Lihua Experimentary Animal Central (Beijing, China).
Rats were housed in a light-controlled room under a 12-h light/
dark cycle with ad libitum access to food and water. The ambient
temperature in the animal room was 20–26uC and the relative
humidity was 40–60% under the care of the Laboratory Animal
Unit, Institute of Zoology, Chinese Academy of Sciences. After
one week of adaptation, the rats were separated into four groups of
ten animals. The PFDoA (CAS No. 307-55-1, 95% purity, Sigma-
Aldrich (St. Louis, MO)) was dissolved in 0.2% Tween-20. The
treatment rats were given doses of 0.05, 0.2, and 0.5 mg PFDoA/
kg body weight/day by oral gavage for 110 days. The control
animals were treated with 0.2% Tween-20 (vehicle) alone. At the
end of the experiment, six rats were selected randomly from each
group and were weighed and euthanized by decapitation. The
remaining four rats from each group were used for another study.
The left kidney of each euthanized rat was removed immediately,
washed with PBS, weighed, divided into four small aliquots, flash
frozen in liquid nitrogen, and stored at 280uC for further analysis.
Samples for the same analysis were from the same region of the
kidney.
Protein preparation and CyDye labeling
Total protein was extracted from the kidney using sample lysis
buffer (7 M urea, 2 M Thiourea, 30 mM Tris, 4% (w/v) CHAPS,
1 mM PMSF and 1% protease inhibitor cocktail (Sigma-Aldrich,
St. Louis, MO). Protein concentration was determined using a 2-D
Quant protein assay kit (GE Healthcare, Uppsala, Sweden).
We chose three groups (0, 0.2, and 0.5 mg/kg/day PFDoA) for
DIGE analysis based on previously observed gene expression
changes in the liver and clinical chemistry parameters [19]. Equal
amounts of protein sample from two randomly selected rats from
the same treatment group were pooled and purified using a 2-D
Clean-up kit (GE Healthcare) for subsequent DIGE analysis. Each
group yielded three pooled protein samples, and the pH values of
the desalted samples were adjusted to 8.5 with 100 mM sodium
hydroxide before labeling. Proteins were labeled with CyDye
Fluor minimal dyes (GE Healthcare) according to the manufac-
turer’s recommended protocols. The internal standard (IS) was
comprised of a pooled equal amount from all experimental
samples. A total of 50 mg of protein from the treated and control
groups were labeled with 400 pmol of either Cy3, Cy5, or Cy2
(Cy2 was used to label the IS). The labeled mixtures were
combined according to Table S1 and were then adjusted to 450 ml
with rehydration buffer (7 M urea, 2 M Thiourea, 2% CHAPS,
0.5% IPG buffer pH 4–7, and a trace of bromophenol blue) prior
to isoelectric focusing (IEF) and subsequent SDS-PAGE.
2-D DIGE and image analysis
The labeled mixtures were loaded onto Immobiline Dry Strips
(24 cm, linear pH gradient from pH 4–7, GE Healthcare). The
IPG strips were rehydrated overnight at 40 V for 5 h followed by
100 V for 6 h, and IEF was then conducted for a total of 78 kVhr
on a Multiphor II System (GE Healthcare). After completion of
the IEF program, the strips were equilibrated and then applied to
12.5% polyacrylamide gels. The SDS-PAGE was performed using
Ettan
TM Dalt six equipment (GE Healthcare) at 15uC. All
electrophoresis procedures were performed in the dark and run
in duplicate. Gels were scanned using a Typhoon
TM Trio Series
Variable Mode Image (GE Healthcare) at 100 mm resolution,
followed by silver staining. The resulting gel images were analyzed
using DeCyder software 6.5 (GE Healthcare). The biological
variation analysis mode (BVA) revealed differences between the
PFDoA treated groups and the control across all gels. A Student’s
t-test was used to statistically analyze the data, and p,0.05 was
considered significant.
In-gel trypsin digestion and protein identification by
MALDI TOF/TOF
Visible differential protein spots were manually excised from the
silver-stained gels and placed into a 96-well microtiter plate. Gel
pieces were destained with 15 mM potassium ferricyanide and
50 mM sodium thiosulfate (1:1) for 20 min at room temperature
and digested overnight with 12.5 ng/ml trypsin in 20 mM
ammonium bicarbonate at 37uC. Peptides were then extracted
twice using 0.1% TFA in 50% ACN, dried, and eluted onto the
target with 0.7 ml of matrix solution (a-cyano-4-hydroxy-cinnamic
acid in 0.1% TFA, 50% ACN). Samples were allowed to air-dry
before being analyzed by an ABI 4700 MALDI-TOF/TOF
Proteomics Analyzer (Applied Biosystems, Framingham, MA,
USA). Positive ion mass spectra were recorded on a home-built
linear time-of-flight mass spectrometer using 39 kV of total
acceleration energy. Data from the PMF and MALDI-TOF
MS/MS were analyzed using MASCOT (Matrix Science,
London, UK) search software. The following parameters were
used in the search: Rattus, protein molecular mass range from 700
to 3,000 Da, trypsin digest with one missed cleavage, peptide
tolerance of 0.2, MS/MS tolerance of 0.8 Da, and possible
oxidation of methionine. Protein scores (based on combined MS
and MS/MS spectra) greater than 56 were considered statistically
significant (p,0.05). The individual MS/MS spectrum with the
statistically significant (confidence interval .95%) best ion score
(based on MS/MS spectra) was accepted. The identified proteins
were then matched to specific processes or functions by searching
Gene Ontology (http://www.geneontology.org/).
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Five differentially expressed proteins (Table S2) were further
examined to detect corresponding mRNA and protein levels in all
experimental groups (0, 0.05, 0.2, and 0.5 mg/kg/day PFDoA) by
quantitative PCR and western blot, respectively. The detailed
methods are given in the Text S1 and Table S2). Hypoxanthine
guanine phosphoribosyltransferase 1 (Hprt1) was chosen as an
internal control by GeNorm analysis [23]. Differences in mRNA
expression levels were calculated using the 2
2DDCt method [24].
For western blot analyses and quantitative PCR data, statistical
significance was determined using a one-way ANOVA followed by
the Duncan multiple range test (SPSS, Inc., Chicago, IL). Data are
presented as means with standard errors (mean6SE). A p-value of
,0.05 was considered statistically significant.
1H NMR spectroscopy of kidney tissues and data analysis
Kidney samples (,250 mg) from the control and PFDoA (0.05,
0.2, and 0.5 mg/kg/day) treatments were homogenized in 2 ml of
50% methanol and then centrifuged at 13,000 rpm for 10 min.
The supernatant was collected, dried under a stream of nitrogen,
and reconstituted in 550 mlo fD 2O. Prior to NMR analysis, 60 ml
of 0.1% sodium salt of 3-(trimethylsilyl)propionic-2,2,3,3,-d4 acid
(TSP) in D2O was added. Two milliliters of chloroform were
added to the pellets (control and 0.5 mg/kg/day PFDoA group),
and the extraction was followed by an additional centrifugation.
The lipophilic supernatants were removed, dried under a stream
of nitrogen, and reconstituted in 600 ml of chloroform-D
(containing 0.03% (v/v) tetramethylsilane) prior to NMR analysis.
The reconstituted solutions were transferred to 5-mm NMR tubes.
The NMR measurements were performed on a Varian INOVA
600 NMR spectrometer at 599.73 MHz, using a 5-mm triple
resonance probe. The 1D NOESY (RD-90u-t1-90u-tm-90u-
acquire) pulse sequence was used for water suppression in the
tissue extracts. For each sample, 64 transients were collected for a
total of 32 K data points. In the lipid extracts, a spectral width of
8,008.0 Hz was acquired with an acquisition time of 2.05 s. In the
aqueous extracts, a spectral width of 8,993.8 Hz and an
acquisition time of 1.82 s were used. Spectra were manually
phased, baseline corrected, and referenced to TMS or TSP at D
0.0. Total correlation spectroscopy (TOCSY) 2D NMR spectra
were also acquired for resonance assignment.
All spectra were manually rephased using the VNMR 6.1C
software package (Varian, Inc., Palo Alto, CA). For lipid extracts,
the spectra were divided into 135 0.04 ppm-wide segments for a
spectral window that ranged from 0.40 to 5.80 ppm. For aqueous
extracts, the spectra were reduced to 900 bins of equal width
(0.01 ppm) corresponding to the D 9.40–0.41 region. The segments
from D 5.1–4.7 ppm were removed to eliminate residual water
resonance. All remaining spectral segments were scaled to the total
integrated area of the spectra to reduce the effects of variation in
concentration[25].The1D
1HNMRspectraldata sets forlipidand
aqueous extracts were imported into the SIMCA-P10.0 software
package (Version 10, Umetrics AB, Umea, Sweden) separately.
Partial least squares discriminant analysis (PLS-DA) with mean
centering was then applied for data processing.
Kidney free amino acid profile analyses
Kidney aqueous extracts (40 ml) were mixed with 10 ml of 10%
sulfosalicyclic acid using an Apricot TPS-24 automated liquid
handler and then centrifuged to precipitate the proteins. Labeling
buffer (40 ml) was added to the supernatant, and the resulting
mixture was incubated with iTRAQH Reagent 115 (5 ml) for
30 min at room temperature. A total of 5 ml of 1.2% hydroxyl-
amine solution was added to each sample. Samples were dried and
reconstituted with the iTRAQH Reagent 114-labeled Standard
Mix (32 ml). Amino acids were separated and detected by an API
3200
TM LC-ESI MS/MS (Applied Biosystems, Framingham,
USA) in positive SRM mode. Chromatography was performed
using a C18 (15064.6 mm) column, with mobile phases of 0.1%
formic acid: 0.01% heptafluorobutyric acid (HFBA): H2O and
0.1% formic acid: 0.01% HFBA: ACN. Total analysis time was
25 min. The concentrations of 42 amino acids were determined by
comparing their ion intensity to their respective internal standards.
Principal components analysis-discriminant analysis (PCA-DA)
was used for data analysis with MarkerView
TM Software and
pareto scaling (Applied Biosystems, Framingham, USA). It is a
supervised multivariate statistical analysis method which combines
PCA with DA to facilitate the classification, similar to PLS-DA.
Results
2-D DIGE analysis for kidney proteins
Kidney proteins were separated effectively by 2-D DIGE
analysis (Figure S1). Analysis by DeCyder software demonstrated
that 129 and 227 spots were significantly altered in the 0.2 and
0.5 mg/kg/day PFDoA groups, respectively, compared to the
control rats (p,0.05), while 68 proteins (16 up-regulated and 52
down-regulated) were significantly altered in both treatments
(Figure 1). One hundred and six protein spots were excised from
the silver-stained gels and identified by MALDI-TOF-MS/MS
analysis. After a MASCOT database search, 79 different proteins
were identified successfully (Figure S1). Some spots were identified
as the same protein by TOF/TOF. This overlap might be due to
different isoforms or differences in posttranslational modifications.
Function categories of identified proteins
The 79 identified proteins are summarized and classified
according to their biological process or function (Table S3).
Twelve of the identified proteins were involved in amino acid
metabolism, including 3-mercaptopyruvate sulfurtransferase
(3Mpst), 3-phosphoglycerate dehydrogenase (Phgdh), and isova-
leryl coenzyme A dehydrogenase (Ivd), which plays an important
role in the metabolism of cysteine (Cys), L-serine, valine (Val),
Figure 1. Venn diagram analysis of the differentially expressed
proteins in two PFDoA treatment groups. The numbers of
differentially expressed spots (up- or down-regulated) in different
treatment groups are shown in the different segments (the number of
identified proteins is given in brackets). T1, 0.2 mg/kg/day PFDoA
group. T2, 0.5 mg/kg/day PFDoA group.
doi:10.1371/journal.pone.0020862.g001
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TCA cycle and pyruvate metabolism. As determined by their
protein expression levels, malate dehydrogenase 1 (Mdh1),
pyruvate carboxylase (PC), pyruvate dehydrogenase (lipoamide)
beta (Pdhb), and succinyl-CoA ligase, GDP-forming, subunit beta
(Suclg2) were all induced by PFDoA. Eight proteins involved in
gluconeogenesis and glycolysis were up-regulated in the kidneys of
rats exposed to 0.2 and 0.5 mg/kg/day of PFDoA. Three spots
(spot 290, 938, and 965) were identified as fructose-1,6-bipho-
sphatase 1, the key regulatory enzyme of gluconeogenesis. Eight
proteins associated with electron transport were all significantly
induced at the protein expression level by PFDoA, including
NADH dehydrogenase (ubiquinone) Fe-S protein 1 (Ndufs1), ATP
synthase (ATP5a1 and ATP5b), and ATPase. Three proteins, Cu-
Zn superoxide dismutase (Cu-Zn SOD), peroxiredoxin 3 (Prx3),
and thioredoxin reductase (TrxR), involved in the elimination of
radical oxygen species (ROS), were up-regulated in the 0.5 mg/
kg/day PFDoA treatment. Prohibitin (Phb) and tumor necrosis
factor type 1 receptor-associated protein (Trap), which are related
to stress response, were also up-regulated.
Quantitative PCR and western blot validation
To authenticate the 2-D DIGE proteomic results and verify
whether changes in protein expression correlated with transcript
level, five proteins related to metabolism (Fbp1, Ivd, Mdh1, Dlat,
and Pc) were selected and analyzed by western blot and quantitative
PCR. The fold changes in these proteins detected by 2-D DIGE in
the 0.2 and 0.5 mg/kg/day PFDoA groups are shown in Table 1.
The western blot results followed a similar pattern to the DIGE
results; except that the protein expression of Fbp1 in the 0.2 mg/
kg/day PFDoA group did not change significantly (p.0.05,
Figure 2). Similar regulation also occurred at the mRNA expression
level. However, the mRNA level of Dlat decreased significantly in
the 0.05 mg/kg/day dosage group (p,0.05) and did not change in
the other two treatments (Figure S2). The low mRNA-protein
correlations were also found by other researchers [26,27]. One of
thereasons is the existenceof posttranscriptional mechanisms which
controls theproteintranslationrate[28] and the half-lives of specific
proteins or mRNAs [29]. These results suggest that PFDoA can
have diverse transcriptional regulation effects, but the protein
concentration changes of some enzymes were probably related to
the change in their transcript levels by PFDoA.
1H NMR spectroscopy of kidney tissue
Typical
1H NMR spectra of the aqueous and lipid extracts of
rats from the control and 0.5 mg/kg dosed group are shown in
Figures 3 and 4, respectively. The
1H chemical shifts and
assignments of the endogenous metabolites were performed
Table 1. Protein expression alteration of five selective proteins from 2-D DIGE analysis.
Protein name Fold change
a (treated vs controls)
0.2 mg/kg/day 0.5 mg/kg/day
fructose-1,6- biphosphatase 1 (Fbp1) 1.12
* 1.01
isovaleryl coenzyme A dehydrogenase (Ivd) 1.06 1.09
**
malate dehydrogenase 1 (Mdh1) 1.04 1.08
*
dihydrolipoamide S-acetyltransferase (Dlat) 1.08 1.14
**
pyruvate carboxylase (Pc) 1.31
** 1.32
aThe average fold changes were determined by Decyder 6.5.
*Significant difference from control, p,0.05.
**Significant difference from control, p,0.01. Positive ratios indicate increased expression of proteins in the PFDoA groups compared to control rats.
doi:10.1371/journal.pone.0020862.t001
Figure 2. Western blot analysis showing the effect of different PFDoA concentrations on protein expression levels of Ivd, Fbp1,
Mdh1, Pc, and Dlat in the kidneys of male rats. Intensities of the proteins were normalized to the corresponding Hprt level. Representative
western blots are shown in (A), and the results from densitometry analysis of the western blots are shown in (B). Each bar represents the mean 6 SE
of six samples per treatment.
*p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0020862.g002
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The
1H NMR spectra of the aqueous tissue extract reflected the
lower molecular weight metabolites present in the kidney
(Figure 3). These metabolites included amino acids, organic acids,
sugars, nucleotides, and their metabolites. The NMR spectra of
lipid extracts were dominated by lipid metabolites, which included
cholesterol esters, triglycerides, saturated and unsaturated fatty
acids, and phosphatides (Figure 4). It was possible to partially
assign resonances from mono- and polyunsaturated fatty acids
based on references [31].
1H NMR spectroscopic and pattern recognition analyses
of the kidney
Preprocessing of data, especially normalization of original data
is a crucial step in metabonomic studies. Total integral
normalization is the most widely used normalization method,
Figure 3. Typical
1H NMR spectra of the aliphatic region (0.8–5.4) and aromatic region (d 5.7–9.1) from aqueous extracts of renal
tissues of (A) control rats and (B) rats exposed to 0.5 mg/kg/d PFDoA. The vertical scales of the aromatic regions are enlarged 8 times. Key:
1. isoleucine; 2. leucine; 3. valine; 4. lactate; 5. alanine; 6. lysine; 7. arginine; 8. acetate; 9. glutamate; 10. glutamine; 11. methionine; 12. DMA; 13. DMG;
14. creatine; 15. ethanolamine; 16. choline; 17. phosphorylcholine; 18. betaine; 19. scyllo-inositol; 20. taurine; 21. glycine; 22. myo-inositol; 23. b-
glucose; 24. a-glucose; 25. uracil; 26. cytidine; 27. tyrosine; 28. phenylalanine; 29. histidine; 30. tryptophan; 31. xanthine; 32. hypoxanthine; 33. inosine;
34. formate; 35. nicotinamide.
doi:10.1371/journal.pone.0020862.g003
Figure 4. Typical
1H NMR spectra of the lipid extracts of renal tissues from (A) control rats and (B) rats exposed to 0.5 mg/kg/d
PFDoA. Chol, cholesterol; TG, triglyceride; PC, phosphatidylcholine; PE, phosphatidylethanolamine.
doi:10.1371/journal.pone.0020862.g004
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spectra’ [34]. This method, however, can fail when there are
abrupt changes in the concentrations of some specific groups of
metabolites or one specific metabolite, such as in the case of
diabetes. There are not strong or abrupt changes of some
metabolites in our data sets, thus we used scaled all remaining
spectral segments to the total integrated area of the spectra to
reduce the effects of variation in concentration [25]. The PLS-
DA model was used to compare
1H NMR spectra from renal
tissue extracts. A dose-dependent tendency for metabolic changes
was demonstrated in the scores plot of the NMR data from the
aqueous extracts (Figure 5). The line loading plot (Figure 5B)
demonstrated the changes in metabolites responsible for the
group separation in Figure 5A. Negative peaks represent
metabolites with higher concentrations in dosed groups than in
the control, whereas positive peaks represent metabolites with
higher concentrations in the control than in the dosed groups.
Consequently, most metabolite levels were elevated, whereas the
concentrations of phosphorylcholine, betaine, glycine, glucose,
and inosine decreased in the PFDoA exposed groups (Table 2).
There were also some variations in the lipid content of renal
tissues in treated rats, as demonstrated in the PLS-DA scores plot
of the lipid extract NMR data for the control and 0.5 mg/kg
dosed rats (Figure S3). The corresponding loading line plot
showed higher content of cholesterol ester, MUFA (except 18:2),
and phosphatidylcholine/phosphatidylethanolamine, and lower
content of TG in the 0.5 mg/kg dosed group than in the control
group.
Rat kidney pools of free amino acids in response to
different doses of PFDoA
We used iTRAQH–LC–MS/MS to measure how kidney amino
acids changed with PFDoA exposure. Results demonstrated that
PFDoA caused significant alterations in the kidney amino acid
profiles based on the analysis of the corresponding loading plot. A
marked increase in sarcosine, Asn, His, 1-methylhistidine, Ile, Leu,
Val,Trp,Tyr),Phe,Cys,andMetintensity,along with adecreasein
the signals of homocitrulline, a-aminoadipic acid, b-alanine, and
cystathionine, were responsible for the separation between the
0.5 mg dosed rats and the control group (Figure 6, Table S4).
Figure 5. Scores scatter plot and loading line plot of the PLS-DA analysis of aqueous renal tissues extracts from control and PFDoA
treated rats. (A) Scores scatter plot for PLS-DA analysis of aqueous renal tissue extracts from control rats (black box &) and rats exposed to
0.05 mg/kg/d (blue dotN), 0.2 mg/kg/d (purple diamond ¤) and 0.5 mg/kg/d (red triangle m) of PFDoA. (B) The loading line plot illustrates the
differentiating metabolites between the treated and control groups. Keys to the metabolites are the same as in Figure 4.
doi:10.1371/journal.pone.0020862.g005
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Perfluorinated carboxylic chemicals, such as PFOA and PFOS,
have been shown to induce hepatomegaly and renal hypertrophy
in male rats when administered orally at a dose of 5 mg/kg/day
for 28 days [35]. In our study, neither the absolute kidney weight
nor the relative kidney weight changed after exposure to PFDoA
for 110 days (data not shown), which is similar to results obtained
by Son et al.[18]. There was, however, a clear elevation in serum
creatine levels in the 0.2 and 0.5 mg/kg/day PFDoA groups [19],
which is a sign of renal insufficiency reflecting lower rates of
glomerular filtration [36]. To better understand potential renal
toxicity of PFDoA, 2-D DIGE, NMR-based metabonomics, and
LC/MS approaches were used in this study. After DIGE and
MALDI-MS analyses, 79 differentially expressed proteins were
identified between the kidneys of untreated and PFDoA treated
rats. These proteins were primarily involved in amino acid
metabolism, carbohydrate and energy metabolism, stress response,
and electron transport. In addition, the NMR- and LC/MS-based
metabolic profile analysis of the kidney samples revealed PFDoA
induced perturbation of glucose and amino acid metabolism in the
kidney.
At the highest dose of PFDoA exposure, the levels of eight of the
twelve differentially expressed proteins related to amino acid
metabolism increased significantly. These proteins included Ivd,
which converts isovaleryl-CoA to 3-methylcrotonyl-CoA as an
intermediate step in the Leu catabolic pathway [37]; Mpst, which
plays a central role in cysteine degradation to pyruvate [38];
glutamine transaminase K (Gtk), a freely reversible glutamine
(methionine) aromatic amino acid aminotransferase [39]; phenyl-
alanine hydroxylase (Pha), which plays a role in phenylalanine
conversion to tyrosine [40]; and L-arginine:glycine amidinotrans-
ferase (Agat), which is involved in arginine-related and creatine
metabolism [41]. Our NMR and LC/MS-based amino acid
profile results showed a marked increase in the levels of branched-
chain amino acids (Val, Leu, and Ile), aromatic amino acids (Phe,
Trp, and Tyr), and other amino acids, including Asn, His, Gln,
Cys, and Met in the 0.5 mg/kg/day PFDoA group, which
illustrates kidney dysfunction caused by PFDoA. These increased
proteins may contribute to the accelerated amino acid metabolism
observed in the kidney after PFDoA treatment. Many of these
elevated proteins are also enzymes involved in amino acid
biochemistry and hence their metabolic contribution to the
observed amino acid profile is an active role. Although catalyzed
by different enzymes, the various amino acids are converted to five
end products (succinate, oxaloacetate, fumarate, a-ketoglutarate,
and pyruvate), which then enter the TCA cycle pathway as
substrates.
In this study, increased expression levels of five proteins (Dlat,
Pdhb, Pc, Mdh1, and Suclg2) suggested an obvious increase in
the rate of the TCA cycle caused by PFDoA. We speculated that
this increase was partly caused by accelerated amino acid
metabolism, as well as the increase in the level of the amino
acid metabolites (lactate, succinate, and pyruvate) in the 0.5 mg/
kg/day PFDoA group. Glucose can also be converted into
pyruvate through the glycolysis pathway. As Enol and Khk are
the two enzymes involved in glycolysis, the up-regulation of these
enzymes in protein levels indicates that glycolysis was accelerated
in kidneys exposed to PFDoA. In addition, glucogenic amino
acids (Val, Leu, Ile, Met, His, Asn, and Cys), lactate, pyruvate,
and intermediate metabolites of the TCA cycle can also enter the
gluconeogenesis pathway as substrates. Both Pc and Mdh1 play
an important role in forming oxaloacetate from pyruvate, and
Fbp1 is the key enzyme of gluconeogenesis. The protein levels of
the five proteins (Pc, Mdh1, Fbp1, Eno1, and Khk) all increased
significantly in the 0.2 and 0.5 mg/kg/day PFDoA groups
compared to the control. This indicates that the enrichment of
amino acid metabolites and glycolysis accelerated the TCA cycle
in the rat kidney. The decrease of glucose in the kidney and
increase in intermediates in the TCA cycle and amino acid
metabolism also stimulated the gluconeogenesis pathway. In
addition, acidosis has been shown to increase renal gluconeo-
genesis, but impair hepatic gluconeogenesis [42]. Since PFDoA is
also a weak acid, it is tempting to speculate that the kidney may
be a major factor in accelerating gluconeogenesis upon PFDoA
exposure.
Table 2. Metabolite changes in renal tissue aqueous extracts
from PFDoA treated rats.
Keys Metabolites
Chemical shift
(multiplicity) Treated vs Control
1 isoleucine 0.95 (t), 1.02 (d) q
2 leucine 0.97 (d) q
3 valine 0.99 (d), 1.05 (d) q
4 lactate 1.33 (d), 4.12 (q) q
5 alanine 1.48(d) q
6 lysine 1.50(m), 1.73(m), 1.90(m) q
7 arginine 1.73(m), 1.90(m) q
8 acetate 1.92(s) q
9 glutamate 2.35(m), q
10 glutamine 2.42(m) q
11 methionine 2.14(s) q
12 dimethylamine 2.73(s) -
13 dimethylglycine 2.91(s) q
14 creatine 3.04(s) q
15 ethanolamine 3.15(t) -
16 choline 3.21(s) q
17 phosphorylcholine 3.23(s) Q
18 betaine 3.27(s), 3.91(s) Q
19 scyllo-inositol 3.35(s) -
20 taurine 3.43(t),3.26(t) q
21 glycine 3.56(s) Q
22 myo-inositol 4.07(m) q
23 b-glucose 4.64(d), 3.2-3.9(m) Q
24 a-glucose 5.23(d), 3.2-3.9(m) Q
25 uracil 7.54(d),5.81(d) -
26 cytidine 7.84(d), 6.07(d), 5.92(d) -
27 tyrosine 7.20(d), 6.90(d) q
28 phenylalanine 7.43(t), 7.39(t), 7.33(d) q
29 histidine 7.86(s), 7.09(s) q
30 tryptophan 7.74(m) -
31 xanthine 7.95(s) q
32 hypoxanthine 8.21(s), 8.19(s) q
33 inosine 8.35(s), 8.23(s), 6.10(d) Q
34 formate 8.46(s) -
35 nicotinamide 8.94(bs), 8.71(m), 8.25(m) q
Note: s, singlet; br, broad single; d, doublet; t, triplet; m, multiplet. The arrows
indicate the increase (q) or decrease (Q) in the levels of metabolites.
doi:10.1371/journal.pone.0020862.t002
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glycolysis, amino acid catabolism, and the TCA cycle are
accompanied by energy metabolism. Among the identified
proteins, seven were enzymes or subunits related to energy
metabolism. Up-regulated proteins such as NADH dehydroge-
nase, ATP synthase (ATP5a1 and ATP5b), and ATPase, which
play important roles in electron transport, showed a significant
induction of mitochondrial respiratory function in rat kidneys
exposed to PFDoA. Mitochondrial respiratory activity is always
accompanied by the production of ROS, which may cause
mitochondrial DNA damage or cell death [43], In this study, the
protein levels of antioxidant enzymes including Cu-Zn SOD,
Figure 6. Scores plot (A) and loading plot (B) of the PCA-DA analysis of kidney pools of free amino acids after exposure to 0.5 mg/
kg/d PFDoA. The full names of amino acids denoted refer to Table S4.
doi:10.1371/journal.pone.0020862.g006
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production of ROS in the kidney. In addition, the classic ‘‘heat
shock’’ chaperones grp75 (Hspa9a) and Hsp60 (Hspd1), which are
associated with the mitochondria [44], were up-regulated. This
result is similar to that obtained in a previous study by Witzmann
et al. [45] These molecular chaperones can regulate protein
turnover and assembly and protect cells from harmful conditions,
including oxidative stress [46]. Coates et al. reported that
prohibitin could be induced by metabolic stress and may play a
role in regulating mitochondrial respiratory activity [47]. Some
researchers have also found that the expression of prohibitin
increased in apoptotic cells [48,49]. Therefore, the observed up-
regulation of these proteins in this study exhibited a preferential
effect of PFDoA on the mitochondria, which might be induced by
the increase in the metabolism of amino acids, carbohydrates, and
energy in rat kidneys exposed to PFDoA. Additionally, taurine is a
ß-amino acid and antioxidant agent naturally found in the kidney
that assists with protection [50,51]. The increase in taurine
concentration observed during metabolic analysis may be a
complementary reaction to PFDoA-induced oxidative damage in
the kidney. Moreover, elevated Myo-inositol, a renal medullary
osmolyte, is a marker of renal medullary injury [52].
Perfluorinated carboxylic chemicals are mainly accumulated in
the liver and kidneys of animals. Han et al. found that 70% of PFOA
are distributed in the cytosolic fraction of the ratkidney,and 40% of
PFOA in male kidney cytosol are protein bound [53]. Organic
anion transporters and some binding proteins, including fatty acid
binding protein and a2u globulin (A2Us), were presumed to play an
important role in the elimination and reabsorption of PFOA in rat
kidneys [54,55]. In addition, A2Us are well known male rat-specific
proteins and include the liver-form and kidney-form a2u-globulins
(A2UL and A2UK). They are capable of binding PFOA in vitro,
although the binding affinity is relatively weak [56]. The globulin
A2UL is synthesized exclusively in the liver of adult male rats [57],
secreted into the blood stream, and freely filtered by the glomerulus
[58]. Approximately 50% of the filtered proteins are excreted in
urine and form the major component of male rat urinary proteins.
The balance is reabsorbed by the epithelial cells of the proximal
tubule [59,60]. Reabsorbed A2UL can be degraded into amino
acids and undergo limited proteolysis to form A2UK. In the present
study, four protein spots were identified as a2u globulin PGCL1
(A2UL1, two spots), a2u globulin PGCL2 (A2UL2), and major
urinary protein 5 (MUP5). Levels of these proteins decreased
significantly in both 0.2 and 0.5 mg/kg/day PFDoA groups, the
maximum being 5.95-fold that of the control. Ciprofibrate, which is
a peroxisome proliferator, represses the amount of a2u-globulin
mRNA and protein in the male rat liver [61]. In our previous study,
PFDoAwasalsoidentifiedasaperoxisomeproliferator[19,62].The
decrease of A2Us in the kidney was possibly due to the repression of
A2U synthesis in the liver in response to PFDoA. The significant
decrease in A2Us could prevent the reabsorption of PFDoA in the
proximal tubule, and consequently slow accumulation of PFDoA in
rat kidneys.
Several limitations of ‘‘-omic’’ techniques as used in the present
study need to be noted. First, some low-abundance proteins, basic
proteins or insoluble membrane-associated proteins may not be
detected using 2-D DIGE analysis. Then, we examined protein
expression from the whole kidney, which could not identify the
localized changes such as those that may be confined to glomeruli
or tubules. Although this can give some information about renal
dysfunction from perturbed proteins and metabolites and reduce
the system errors as much as possible; however, this may affect the
magnitude of changes in individual intrarenal structures. In
addition, we examined renal protein expression at only one time-
point, which did not represent the entire dynamic process of PFCs
nephrotoxicity. Finally, due to the complexity of biological
processes in organisms, including feedforward, feedback and open
loop, the detail causality of the changes could not be clarified from
one or several ‘‘-omics’’ research in vivo. But what we could do was
to put forward a potential toxicity and the probable consequences
of effects as far as possible in this study, as well as yield new insights
into PFCs nephrotoxictity. Therefore, further studies including in
vitro and in vivo tests, detection of time-courses of effects and
changes in individual regions of kidneys would shed more light on
the definite proteins’ functional roles and the consequence of these
effects observed herein.
In summary, this paper reports the renal toxicity induced by
PFDoA as determined by proteomics and NMR- and LC/MS-
based metabonomics. The changes in the proteomic and
metabonomic profiles showed that PFDoA could cause kidney
damage, primarily perturbing kidney glucose and amino acid
metabolism and inducing mitochondrial disorders and oxidative
stress to the kidney. Furthermore, the decrease in A2Us possibly
prevents PFDoA-induced nephrotoxicity by repressing reabsorp-
tion of PFDoA in the proximal tubule and decelerating PFDoA
accumulation in the kidney. Our study provides information on
the broad and potential effect of PFDoA on the kidney based on
levels of proteins and metabolites.
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